Endo International plc
Endo International plc (ENDP): 4 pipeline candidates · ~22 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
21.7 months
0% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Endo International plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$1.0B
Quarterly Burn
$168.6M
Runway
21.7 mo
Revenue
$497.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| day 1 higher dose | Phase 2 |
| day 1 lower dose | Phase 2 |
| tlc599 | Phase 3 |
| xiaflex | Preclinical |
Frequently asked questions
How many drug candidates are in Endo International plc's pipeline?
Endo International plc (ENDP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Endo International plc's lead drug candidate?
Endo International plc's most advanced tracked candidate is day 1 higher dose (Phase 2) for Lassa Fever.
What is Endo International plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Endo International plc has approximately 21.7 months of cash runway.
Get the full picture on Endo International plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.